Report Publication Announcement • May 13, 2016
Report Publication Announcement
Open in ViewerOpens in native device viewer
Lyon, May 13th, 2016 - Adocia (Euronext Paris: FR0011184241 - ADOC) will hold its annual shareholders' meeting ("AGM") on June 21, 2016, at 10:30 am at Hôtel de Talleyrand, at Jones Day offices, 2 rue Saint-Florentin, in Paris (75001).
The notice of this shareholders' meeting serving as convening notice published today, in the French Bulletin des Annonces Légales Obligatoires ("BALO") includes the agenda, the proposed resolutions as well as instructions to participate and vote for this meeting. This notice is also available on the company's website: http://www.adocia.fr/WP/investors-welcome/shareholders-meeting.
All documentation regarding this AGM will be made available to shareholders in accordance with existing regulations and will be available on the company's website from May 31, 2016.
Only shareholders having registered their shares at least two business days prior to the date of the AGM, by midnight Paris time, will be able to participate in the AGM.
Shareholders holding bearer shares ("actions au porteur") will need to obtain an certificate of shareholding ("attestation de participation") from their brokers. This "attestation de participation" must be attached to the proxy form or to the appropriate voting form if shareholders wish to designate a proxy or vote by post. The "attestation de participation" may replace the admission card for shareholders wishing to attend the AGM in person.
Written questions from shareholders must be received at the latest four business days prior to the AGM by registrered letter, addressed to the registered office, or by e-mail to [email protected].
Shareholders may obtain the legal documentation in preparation of the AGM as described in the article R.225-83 of the French Commercial Code by sending a request:
Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of already-approved therapeutic proteins. Adocia's insulin formulation portfolio, featuring four clinical-stage programs and one preclinical program, is among the largest and most differentiated in the industry.
The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone to each protein for a given application in order to address specific patient needs.
Adocia's clinical pipeline includes a unique formulation of PDGF-BB for the treatment of diabetic foot ulcer and four novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analogs (BioChaperone Lispro U100 and U200), a rapid-acting formulation of human insulin (HinsBet U100) and a combination of insulin glargine and a rapid-acting insulin analog (BioChaperone Combo). Adocia is also developing a concentrated, rapidacting formulation of human insulin (HinsBet U500).
In December 2014, Adocia signed a partnership with Eli Lilly for the development and commercialization of the BioChaperone Lispro programs.
Adocia's extended, early-stage programs include innovative monoclonal antibody formulations, featuring two ongoing collaborations programs with major pharmaceutical companies in the field, and the delivery of anticancer drugs using the proprietary DriveIn® nanotechnology platform.
Adocia aims to deliver "Innovative medicine for everyone, everywhere."
To learn more about Adocia, please visit us at www.adocia.com
| Adocia | Adocia Press Relations France | Adocia Press Relations Europe |
|---|---|---|
| Gérard Soula | ALIZE RP | MC Services AG |
| Chairman and CEO | Caroline Carmagnol et Florence | Raimund Gabriel |
| [email protected] | Portejoie | [email protected] |
| Tél. : +33 4 72 610 610 | [email protected] | [email protected] |
| [email protected] | Tél. : +49 89 210 228 0 | |
| Tél. : + 33 1 44 54 36 61 |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.